Skip to main content
Claudio Brunstein, MD, Hematology, Cleveland, OH, M Health Fairview University of Minnesota Medical Center

ClaudioGarciaBrunsteinMDPhD(He/Him)

Hematology Cleveland, OH

Hematologic Oncology

Cleveland Clinic Foundation, Cleveland, OH

Dr. Brunstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Brunstein's full profile

Already have an account?

Education & Training

  • University of Minnesota
    University of MinnesotaFellowship, Hematology and Medical Oncology, 1998 - 2002
  • Federal University of Rio Grande do Sul School of Medicine
    Federal University of Rio Grande do Sul School of MedicineClass of 1990

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2022 - 2026
  • MN State Medical License
    MN State Medical License 2002 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics  
    Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

  • Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
    Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
    Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Uni...
    Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • University of Minnesota Opens First-Ever U.S. Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood Cancer
    University of Minnesota Opens First-Ever U.S. Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood CancerOctober 23rd, 2019
  • First-Ever US Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood Cancer
    First-Ever US Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood CancerOctober 21st, 2019
  • Half-Matched Transplants Widen Pool of Donors for Leukemia and Lymphoma
    Half-Matched Transplants Widen Pool of Donors for Leukemia and LymphomaJuly 8th, 2011

Hospital Affiliations